Rezolute, Inc. (RZLT) Investor Relations Documents

Rezolute, Inc. (RZLT) investor relations documents from the company's IR site: 1 presentation, 27 press releases; latest deck 2026-05-27. Read in-app with summaries. First-party data.

Corporate Presentation - May 2026 View Presentation: Rezolute is a late-stage biotech developing ersodetug (RZ358) for hyperinsulinism, currently reporting Phase 3 sunRIZE study results and future clinical plans.

Investor relations documents — source: company IR site
PublishedTypeDocument
2026-07-21Press releaseRezolute to Participate in the BTIG Virtual Biotechnology Conference
2026-06-17Press releaseRezolute Highlights Results Presented from Natural History Outcomes Studies and its Ersodetug Clinical Program in Hyperi
2026-06-04Press releaseRezolute Announces Four Presentations at the Upcoming Annual Meeting of the Endocrine Society
2026-06-02Press releaseRezolute Announces Positive Interim Data for its Phase 3 upLIFT Study of Ersodetug in Tumor Hyperinsulinism
2026-05-27PresentationCorporate Presentation - May 2026 View Presentation
2026-05-12Press releaseDownload as PDF
2026-05-12Press releaseRezolute Reports Third Quarter Fiscal 2026 Financial Results and Provides Business Update
2026-05-01Press releaseRezolute Announces Oral Presentation of Results From its Phase 3 sunRIZE Study of Ersodetug in Patients with Congenital
2026-04-21Press releaseRezolute to Present Results from its Phase 3 sunRIZE Study in Congenital Hyperinsulinism at the Pediatric Endocrine Soci
2026-03-24Press releaseRezolute Provides Update on its Congenital Hyperinsulinism Program Following FDA Meeting
2026-03-04Press releaseRezolute to Participate in the Citizens Life Sciences Conference
2026-02-12Press releaseRezolute Reports Second Quarter Fiscal 2026 Financial Results and Provides Business Update
Press releaseRezolute Reports First Quarter Fiscal 2026 Financial Results and Provides Business Update
Press releaseRezolute Reports Third Quarter Fiscal 2025 Financial Results and Provides Business Update
Press releaseRezolute Reports Second Quarter Fiscal 2025 Financial Results and Provides Business Update
2024-09-19Press releaseRezolute Reports Fourth Quarter and Full Year Fiscal 2024 Financial Results and Provides Business Update
2024-05-15Press releaseRezolute Reports Third Quarter Fiscal 2024 Financial Results and Provides Business Update
2024-02-13Press releaseRezolute Reports Second Quarter Fiscal 2024 Results and Provides Business Update
2023-11-13Press releaseRezolute Reports First Quarter Fiscal 2024 Results
2023-09-14Press releaseRezolute Reports Full Year Fiscal 2023 Results and Highlights Company Progress
2023-05-11Press releaseRezolute Reports Third Quarter Fiscal 2023 Results and Highlights Company Progress
2023-02-10Press releaseRezolute Reports Second Quarter Fiscal 2023 Results and Highlights Company Progress
2022-11-09Press releaseRezolute Reports First Quarter Fiscal 2023 Results and Highlights Company Progress
2022-09-15Press releaseRezolute Reports Fourth Quarter and Full Year Fiscal 2022 Results and Highlights Company Progress
2022-05-12Press releaseRezolute Reports Third Quarter Fiscal 2022 Financial Results and Highlights Company Progress
Press releaseRezolute Reports Second Quarter Fiscal 2022 Financial Results and Highlights Company Progress
Press releaseRezolute Reports First Quarter Fiscal 2022 Financial Results and Highlights Recent Company Progress
Press releaseRezolute Reports Second Quarter Fiscal 2021 Financial Results

RZLT overview · RZLT earnings · RZLT financials · RZLT KPIs · RZLT ownership · RZLT peers · RZLT filings

Documents published by the company on its investor-relations site; summaries are model-written. Not personalized investment advice.